Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONGSTEM: HepaStem Long-Term Safety Registry
2017-003989-27Phase 2Active
- Sponsor
- Promethera Therapeutics
- Start
- Nov 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hepastem in urea cycle disorder (UCD), Crigler-Najjar syndrome (CNS), hepatic disease and 1 more, sponsored by Promethera Therapeutics. Primary endpoint: Occurrence of Adverse Events of Specific Interest (AESI). Started Nov 2017; status: active.
02
Drugs
hepastem
03
Conditions
urea cycle disorder (UCD)Crigler-Najjar syndrome (CNS)hepatic diseaseCongenital Metabolic Diseases
Beyond the preview
Go deeper on 2017-003989-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003989-27.